Longeveron LLC, a regenerative medicine company developing cellular therapies, announced that it treated its first patient in the Company’s Phase 2b clinical trial evaluating the safety and efficacy of Longeveron

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In